Carmustine
- Generic Name
- Carmustine
- Brand Names
- Bicnu, Gliadel, Carmustine medac (previously Carmustine Obvius)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H9Cl2N3O2
- CAS Number
- 154-93-8
- Unique Ingredient Identifier
- U68WG3173Y
- Background
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index,...
- Indication
For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
- Associated Conditions
- Astrocytoma, Brain Stem Gliomas, Ependymoma, High Grade Glioma: Glioblastoma (GBM), Medulloblastomas, Metastatic Brain Tumors, Mycosis Fungoides (MF), Newly Diagnosed High-Grade Glioma, Recurrent Glioblastoma Multiforme (GBM), Refractory Hodgkin Lymphoma, Refractory Multiple Myeloma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Eric Jacobsen, MD
- Target Recruit Count
- 24
- Registration Number
- NCT06692452
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 36
- Registration Number
- NCT06687772
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Tebentafusp-tebn With LDT in Metastatic UM
- Conditions
- Interventions
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 109
- Registration Number
- NCT06626516
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 28
- Registration Number
- NCT06377540
Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL
- Conditions
- Interventions
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT05863845
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
- Conditions
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT05521984
- Locations
- 🇺🇸
Washington University School of Medicine/St. Louis Children's Hospital, Saint Louis, Missouri, United States
ChiCGB vs BEAM in High-risk or R/R Lymphomas
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 306
- Registration Number
- NCT05466318
- Locations
- 🇨🇳
Chengdu Third People's Hospital, Chendu, Sichuan, China
🇨🇳People's Hospital of Deyang City, Deyang, Deyang, China
🇨🇳West China Hospital, Sichuan University, Chendu, Sichuan, China
Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell LymphomaRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT05228249
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Leland Metheny
- Target Recruit Count
- 16
- Registration Number
- NCT05052957
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT04871607
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.